This company has been acquired
Pardes Biosciences Past Earnings Performance
Past criteria checks 0/6
Pardes Biosciences's earnings have been declining at an average annual rate of -1.6%, while the Biotechs industry saw earnings growing at 23.7% annually.
Key information
-1.6%
Earnings growth rate
45.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -49.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Revenue & Expenses BreakdownBeta
How Pardes Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -76 | 26 | 57 |
| 31 Mar 23 | 0 | -93 | 28 | 70 |
| 31 Dec 22 | 0 | -97 | 29 | 70 |
| 30 Sep 22 | 0 | -87 | 27 | 61 |
| 30 Jun 22 | 0 | -75 | 23 | 52 |
| 31 Mar 22 | 0 | -55 | 17 | 38 |
| 31 Dec 21 | 0 | -39 | 10 | 28 |
| 30 Sep 21 | 0 | -36 | 7 | 21 |
| 30 Jun 21 | 0 | -27 | 4 | 15 |
| 31 Mar 21 | 0 | -20 | 2 | 9 |
Quality Earnings: PRDS is currently unprofitable.
Growing Profit Margin: PRDS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PRDS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PRDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Return on Equity
High ROE: PRDS has a negative Return on Equity (-49%), as it is currently unprofitable.